【ChiCTR2100049126】Efficacy of Thiamine in Patients with Clinically Suspected Dry Beriberi: An Open Labeled Hospital Based Study in Bangladesh
ChiCTR2100049126
结束
/
/
/
2021-07-21
/
/
dry beriberi
Efficacy of Thiamine in Patients with Clinically Suspected Dry Beriberi: An Open Labeled Hospital Based Study in Bangladesh
Efficacy of Thiamine in Patients with Clinically Suspected Dry Beriberi: An Open Labeled Hospital Based Study in Bangladesh
4203
General objective: To evaluate the efficacy of Thiamine in patients with suspected / possible dry beriberi Specific objectives: 1. To describe the socio-demographic profile of patients; 2. To categorize the patients according to their presenting symptoms and signs; 3. To assess and compare pre and post treatment neurological features.
单臂
回顾性研究
N/A
N/A
self funding
/
55
/
2018-07-01
2018-06-30
/
1. Any person admitted to CMCH as a Suspected/Possible dry-beriberi. Risk factors + at least 2 of the following signs: Risk factors include Imbalanced diet (diet poor in thiamine/rich in carbohydrate or anti-thiamine factors), malnutrition, alcoholism, GIT surgery, chronic diarrhoea, chronic vomiting, pregnancy or history of recent delivery, chronic. diuretics use, renal dialysis, total parenteral nutrition. 1) Muscle weakness of upper and or lower limb (less than grade 5 power in MRC scale); 2) Positive sensory symptoms (burning, tingling or pain); 3) Objective sensory deficit (pain, touch, position, vibration sense); 4) Absent or reduced deep tendon reflexes; 5) Positive squat test (unable to rise after squatting without help);6) Leg swelling; 2. Aged 18 years and above.；
请登录查看1. Patients with isolated cardiac/wet beriberi; 2. Patient with known causes of peripheral neuropathy such as Diabetic, hereditary, Demyelinating (GBS, CIDP), metabolic (hepatic/renal impairment), drugs (e.g. INH, Ethambutol, Phenytoin, Metronidazole, Dapsone etc.) Toxin (As ,OPC, Pb ,Hg except alcohol) etc.; 3. Patients refuse to participate.；
请登录查看Dr. Nayema Masrura
4203
Dr. Nayema Masrura的其他临床试验
孟加拉国热带病与传染病研究所的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04